Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
33 hedge funds and large institutions have $52.8M invested in Astria Therapeutics in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0% more funds holding
Funds holding: 33 → 33 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
35% less capital invested
Capital invested by funds: $81.4M → $52.8M (-$28.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$858K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$670K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$230K |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$223K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$87.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
-$357K |
| 2 |
FAM
Fred Alger Management
New York
|
-$247K |
| 3 |
Millennium Management
New York
|
-$205K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$107K |
| 5 |
D.E. Shaw & Co
New York
|
-$70.7K |
ATXS Hedge Fund Activity: Q1 2016 in Review
33 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2016, worth a combined $52.8M — down 35% from $81.4M a quarter earlier.
Fund positioning in ATXS was balanced in Q1 2016: 6 funds opened new positions, 6 closed out, 12 added to existing stakes and 8 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $858K. The largest seller was Tocqueville Asset Management, exiting entirely with an estimated $357K sold.
- 33 institutional investors held Astria Therapeutics (ATXS) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $52.8M of Astria Therapeutics stock for Q1 2016, down 35% quarter-over-quarter.
- 6 funds opened new Astria Therapeutics positions in Q1 2016 and 6 closed out, a net change of 0 holders.
- The largest Astria Therapeutics buyer in Q1 2016 was Sphera Funds Management, an estimated $858K added.
- The largest Astria Therapeutics seller in Q1 2016 was Tocqueville Asset Management, an estimated $357K sold.
Based on aggregated 13F filings for Q1 2016.